Form 4: Avadel CFO Disposes Shares in Alkermes Acquisition

Avadel Pharmaceuticals CFO Thomas S. McHugh disposed of all ordinary shares and stock options following the company's acquisition by Alkermes plc for $21.00 cash plus a contingent value right per share.

Summary

• Thomas S. McHugh, Chief Financial Officer of Avadel Pharmaceuticals PLC, reported the disposition of all his beneficial ownership in the company.
• The disposition occurred on February 12, 2026, coinciding with the effective time of Avadel's acquisition by Alkermes plc.
• Each outstanding ordinary share was converted into $21.00 in cash and a non-transferable contingent value right (CVR) for a potential additional $1.50 per share.
• Restricted Stock Awards vested fully and were treated identically to ordinary shares.
• Stock options were canceled and exchanged for cash, calculated as the difference between the $21.00 cash consideration and the option's exercise price, plus one CVR per share subject to the option.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event for Avadel shareholders, as it provides a clear exit strategy with a fixed cash payment and potential upside from CVRs, albeit with the loss of independent company upside.

Positives

• Shareholders received a fixed cash consideration of $21.00 per ordinary share.
• Potential for an additional $1.50 per share via a Contingent Value Right (CVR) upon achievement of certain milestones.
• Restricted Stock Awards vested in full, providing immediate value to holders.
• Stock options were converted to cash and CVRs, providing liquidity and potential upside.

Negatives

• Avadel Pharmaceuticals PLC will cease to exist as an independent publicly traded entity following the acquisition.
• Shareholders no longer participate in the future growth or operational performance of Avadel beyond the CVR terms.

Risks

• The additional $1.50 per share from the Contingent Value Right (CVR) is contingent upon the achievement of certain unspecified milestones, meaning it is not guaranteed.

Future Outlook

The filing indicates the completion of Avadel Pharmaceuticals plc's acquisition by Alkermes plc, meaning Avadel will no longer operate as an independent entity. Future value for former Avadel shareholders is tied to the performance of Alkermes and the achievement of milestones for the Contingent Value Rights.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation event within the pharmaceutical sector, where larger players often acquire smaller, specialized companies to expand their product pipelines or market share. Such transactions typically offer a premium to the acquired company's shareholders, providing an exit strategy and immediate liquidity.

Stakeholder Impact

• Shareholders: Received $21.00 cash per share and a Contingent Value Right (CVR) for a potential additional $1.50 per share.
• Employees (including reporting person): Equity awards (Restricted Stock Awards and Stock Options) were converted into cash and CVRs.

Key Dates

Keywords

Avadel Pharmaceuticals, AVDL, Alkermes, Acquisition, Merger, Form 4, Insider Trading, Beneficial Ownership, CFO, Contingent Value Right, CVR, Scheme of Arrangement